Zobrazeno 1 - 10
of 423
pro vyhledávání: '"Frederick L. Locke"'
Autor:
Pierre Sesques, Amy A. Kirkwood, Mi Kwon, Kai Rejeski, Michael D. Jain, Roberta Di Blasi, Gabriel Brisou, François-Xavier Gros, Fabien le Bras, Pierre Bories, Sylvain Choquet, Marie-Thérèse Rubio, Gloria Iacoboni, Maeve O’Reilly, René-Olivier Casasnovas, Jacques-Olivier Bay, Mohamad Mohty, Magalie Joris, Julie Abraham, Cristina Castilla Llorente, Mickael Loschi, Sylvain Carras, Adrien Chauchet, Laurianne Drieu La Rochelle, Olivier Hermine, Stéphanie Guidez, Pascale Cony-Makhoul, Patrick Fogarty, Steven Le Gouill, Franck Morschhauser, Thomas Gastinne, Guillaume Cartron, Marion Subklewe, Frederick L. Locke, Robin Sanderson, Pere Barba, Roch Houot, Emmanuel Bachy
Publikováno v:
Journal of Hematology & Oncology, Vol 17, Iss 1, Pp 1-10 (2024)
Abstract Autologous anti-CD19 chimeric antigen receptor (CAR) T cells are now used in routine practice for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Severe (grade ≥ 3) cytokine release syndrome (CRS) and immune effector cell-associate
Externí odkaz:
https://doaj.org/article/8b4e23a2ec6b43d29b08dcb92f281971
Autor:
Saurabh Zanwar, Surbhi Sidana, Leyla Shune, Omar Castaneda Puglianini, Oren Pasvolsky, Rebecca Gonzalez, Danai Dima, Aimaz Afrough, Gurbakhash Kaur, James A. Davis, Megan Herr, Hamza Hashmi, Peter Forsberg, Douglas Sborov, Larry D. Anderson Jr, Joseph P. McGuirk, Charlotte Wagner, Alex Lieberman-Cribbin, Adriana Rossi, Ciara L. Freeman, Frederick L. Locke, Shambavi Richard, Jack Khouri, Yi Lin, Krina K. Patel, Shaji K. Kumar, Doris K. Hansen
Publikováno v:
Journal of Hematology & Oncology, Vol 17, Iss 1, Pp 1-11 (2024)
Abstract Idecabtagene vicleucel (Ide-cel) has demonstrated excellent efficacy and durable responses in patients with relapsed/refractory multiple myeloma (RRMM). However, the outcomes with ide-cel in patients with extramedullary disease (EMD) remain
Externí odkaz:
https://doaj.org/article/681de79c8e1349a19906516ee568e2af
Autor:
Aimaz Afrough, Hamza Hashmi, Doris K. Hansen, Surbhi Sidana, Chul Ahn, Lauren C. Peres, Danai Dima, Ciara L. Freeman, Omar Castaneda Puglianini, Mehmet H. Kocoglu, Shebli Atrash, Peter M. Voorhees, Leyla Shune, Joseph P. McGuirk, Gary Simmons, Douglas W. Sborov, James A. Davis, Gurbakhash Kaur, Aishwarya Sannareddy, Christopher J. Ferreri, Mahmoud R. Gaballa, Scott Goldsmith, Omar Nadeem, Shonali Midha, Charlotte B. Wagner, Frederick L. Locke, Krina K. Patel, Jack Khouri, Larry D. Anderson, Yi Lin
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-5 (2024)
Externí odkaz:
https://doaj.org/article/3e7b6b54104143d6819770a8ea596373
Autor:
Christopher J. Ferreri, Michelle A. T. Hildebrandt, Hamza Hashmi, Leyla O. Shune, Joseph P. McGuirk, Douglas W. Sborov, Charlotte B. Wagner, M. Hakan Kocoglu, Aaron Rapoport, Shebli Atrash, Peter M. Voorhees, Jack Khouri, Danai Dima, Aimaz Afrough, Gurbakhash Kaur, Larry D. Anderson, Gary Simmons, James A. Davis, Nilesh Kalariya, Lauren C. Peres, Yi Lin, Murali Janakiram, Omar Nadeem, Melissa Alsina, Frederick L. Locke, Surbhi Sidana, Doris K. Hansen, Krina K. Patel, Omar Alexis Castaneda Puglianini
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract Most patients with multiple myeloma experience disease relapse after treatment with a B-cell maturation antigen-targeted therapy (BCMA-TT), and data describing outcomes for patients treated with sequential BCMA-TT are limited. We analyzed cl
Externí odkaz:
https://doaj.org/article/ba30b147cb5a40229e9257f0ed0c5838
Autor:
Kai Rejeski, Doris K. Hansen, Radhika Bansal, Pierre Sesques, Sikander Ailawadhi, Jennifer M. Logue, Eva Bräunlein, David M. Cordas dos Santos, Ciara L. Freeman, Melissa Alsina, Sebastian Theurich, Yucai Wang, Angela M. Krackhardt, Frederick L. Locke, Emmanuel Bachy, Michael D. Jain, Yi Lin, Marion Subklewe
Publikováno v:
Journal of Hematology & Oncology, Vol 16, Iss 1, Pp 1-13 (2023)
Abstract Background BCMA-directed CAR T-cell therapy (CAR-T) has altered the treatment landscape of relapsed/refractory (r/r) multiple myeloma, but is hampered by unique side effects that can lengthen hospital stays and increase morbidity. Hematologi
Externí odkaz:
https://doaj.org/article/781664a000bf43b0842a034c8f0fd087
Autor:
Dae Hyun Lee, Sanjay Chandrasekhar, Michael D. Jain, Rahul Mhaskar, Kayla Reid, Sae Bom Lee, Salvatore Corallo, Melanie J. Hidalgo-Vargas, Abhishek Kumar, Julio Chavez, Bijal Shah, Aleksandr Lazaryan, Farhad Khimani, Taiga Nishihori, Christina Bachmeier, Rawan Faramand, Michael G. Fradley, Daniel Jeong, Guilherme H. Oliveira, Frederick L. Locke, Marco L Davila, Mohammed Alomar
Publikováno v:
Cardio-Oncology, Vol 9, Iss 1, Pp 1-9 (2023)
Abstract Background Chimeric antigen receptor T- Cell (CAR-T) immunotherapy has been a breakthrough treatment for various hematological malignancies. However, cardiotoxicities such as new-onset heart failure, arrhythmia, acute coronary syndrome and c
Externí odkaz:
https://doaj.org/article/2b3320c84568447e825867b260a94475
Autor:
Aya G. Elmarsafawi, Rebecca S. Hesterberg, Mario R. Fernandez, Chunying Yang, Lancia N.F. Darville, Min Liu, John M. Koomen, Otto Phanstiel IV, Reginald Atkins, John E. Mullinax, Shari A. Pilon-Thomas, Frederick L. Locke, Pearlie K. Epling-Burnette, John L. Cleveland
Publikováno v:
JCI Insight, Vol 8, Iss 18 (2023)
Glutaminolysis is a hallmark of the activation and metabolic reprogramming of T cells. Isotopic tracer analyses of antigen-activated effector CD8+ T cells revealed that glutamine is the principal carbon source for the biosynthesis of polyamines putre
Externí odkaz:
https://doaj.org/article/b2a468345105429b88b1c9a8b533e6c4
Autor:
Jung W. Choi, Erin A. Dean, Hong Lu, Zachary Thompson, Jin Qi, Gabe Krivenko, Michael D. Jain, Frederick L. Locke, Yoganand Balagurunathan
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
The Metabolic Tumor Volume (MTV) and Tumor Lesion Glycolysis (TLG) has been shown to be independent prognostic predictors for clinical outcome in Diffuse Large B-cell Lymphoma (DLBCL). However, definitions of these measurements have not been standard
Externí odkaz:
https://doaj.org/article/cb6b780ea3d44c4880f11cf1d9fbe271
Autor:
Semira Sheikh, Sepideh Mokhtari, Jeffrey A. Silverman, Kayla Reid, Rawan Faramand, Marco L. Davila, Norman Franke, Frederick L. Locke, Michael D. Jain, Daniel Wong, John G. Kuruvilla
Publikováno v:
eJHaem, Vol 3, Iss 1, Pp 223-227 (2022)
Externí odkaz:
https://doaj.org/article/13b8610a64c74b59a0dc98940dbbade2
Autor:
Laura B. Oswald, Lisa M. Gudenkauf, Xiaoyin Li, Gabriel De Avila, Lauren C. Peres, Kedar Kirtane, Brian D. Gonzalez, Aasha I. Hoogland, Oanh Nguyen, Yvelise Rodriguez, Rachid C. Baz, Kenneth H. Shain, Melissa Alsina, Frederick L. Locke, Ciara Freeman, Omar Castaneda Puglianini, Taiga Nishihori, Hien Liu, Brandon Blue, Ariel Grajales-Cruz, Heather S. L. Jim, Doris K. Hansen
Publikováno v:
Cancers, Vol 15, Iss 19, p 4711 (2023)
Idecabtagene vicleucel (ide-cel) was the first FDA-approved chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma (RRMM) patients. This was the first study to evaluate patient-reported outcomes (PROs) among RRMM patients r
Externí odkaz:
https://doaj.org/article/a15db1658ca5412090eb9f37cd05b031